We have located links that may give you full text access.
Journal Article
Research Support, Non-U.S. Gov't
Review
Pembrolizumab in the preoperative setting of triple-negative breast cancer: safety and efficacy.
Expert Review of Anticancer Therapy 2020 November
INTRODUCTION: In 2019, the PD-L1 inhibitor atezolizumab became the first immune checkpoint inhibitor approved for treatment in patients with breast cancer. The approval is restricted to patients with metastatic triple-negative breast cancer (TNBC) whose tumors are PD-L1 positive. There is a rationale to believe that using PD-1/L1 inhibitors in the early disease setting may be associated with even greater benefit than seen in the metastatic setting.
AREAS COVERED: We review the results of pembrolizumab studies in the metastatic setting as well as the rationale for using immunotherapy in the preoperative setting. We also present current data pembrolizumab in the treatment of breast cancer with focus on the early-stage setting and discuss areas of uncertainty.
EXPERT OPINION: The KEYNOTE-552 study showed, for the first time, that the addition of pembrolizumab to preoperative chemotherapy increases pathologic complete response rates. Event-free survival data are promising and longer follow-up is needed to determine whether the addition of pembrolizumab significantly improves long-term outcomes for patients with early-stage TNBC.
AREAS COVERED: We review the results of pembrolizumab studies in the metastatic setting as well as the rationale for using immunotherapy in the preoperative setting. We also present current data pembrolizumab in the treatment of breast cancer with focus on the early-stage setting and discuss areas of uncertainty.
EXPERT OPINION: The KEYNOTE-552 study showed, for the first time, that the addition of pembrolizumab to preoperative chemotherapy increases pathologic complete response rates. Event-free survival data are promising and longer follow-up is needed to determine whether the addition of pembrolizumab significantly improves long-term outcomes for patients with early-stage TNBC.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app